TISIDB

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF09341 Transcription factor Pcc1
Function	-

> Gene Ontology [ TOP ]
Biological Process	-
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CTAG1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CTAG1B and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19276262	Melanoma	Promote immunity	NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. The proportion of patients with circulating NY-ESO-1-specific CD4(+) T cells was also reduced, and although many patients had CD8(+) T cells specific to a broad range of NY-ESO-1 epitopes, the majority of these responses were preexisting.
18240144	Glioma	Promote immunity (T cell function); essential for immunotherapy	In an orthotopic xenograft model, the systemic administration of 5-aza-CdR resulted in a significant volume reduction of the transplanted tumors and prolonged the survival of the animals after the adoptive transfer of NY-ESO-1-specific CTLs.
21413013	Esophageal Carcinoma; Prostate carcinoma	Promote immunity (T cell function)	In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1-expressing tumors with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and showed efficient induction of NY-ESO-1 antibody, and CD4 and CD8 T cell responses using peripheral blood from the patients.
22936067	Myxoid Liposarcoma	Promote immunity	In all, 7/8 (88%) and 16/18 (89%) myxoid and round cell expressed CTAG1B and NY-ESO-1 by quantitative real-time PCR and immunohistochemistry, respectively. Our study shows that both CTAG1B mRNA and protein are overexpressed with high frequency in myxoid and round cell liposarcoma, enabling the potential use of targeted immunotherapy in the treatment of this malignancy.
23312906	Glioma; Mesothelioma	Promote immunity	In two non epithelial cancers (glioma and mesothelioma), we found that the epigenetic regulation of the NY-ESO1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes.The NY-ESO1 gene is a cancer/testis antigen considered to be suitable target for the immunotherapy of human malignancies.

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CTAG1B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CTAG1B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	1.157	0.174
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.468	0.275
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.912	0.447
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.306	0.137
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.47	0.344
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.107	0.579
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.323	0.82
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.385	0.849
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.118	0.96
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.013	0.868

> Mutation difference between responders and non-responders [ TOP ]
There is no record.

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTAG1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTAG1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTAG1B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTAG1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CTAG1B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CTAG1B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CTAG1B
Name	cancer/testis antigen 1B
Aliases	NY-ESO-1; CTAG; CTAG1; New York esophageal squamous cell carcinoma 1; cancer antigen 3
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CTAG1B collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CTAG1B